A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Study sponsor: Cognition Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-05-29Actual
Enrollment · participants153Actual
Source updated2025-08-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.